Henry M. Jackson Foundation for the Advancement of Military Medicine

Advancing Military Medicine

Search Results - %ce%b2-thalassemia

2 Results Sort By:
SETBP1 and XPO1 inhibitors for the treatment of Sickle cell disease and β- Thalassemia - (HJF 547-19)
Researchers at the Uniformed Services University for the Health Sciences (USU) and HJF have developed small molecules that can be used to reactivate embryonic and fetal hemoglobin expression for use as therapeutics for sickle-cell disease (SCD) and β-Thalassemia. Applications and Advantages Effective inducing of embryonic and fetal hemoglobin...
Published: 12/12/2024   |   Updated: 1/25/2023   |   Inventor(s): Yang (Dennis) Du, Nhu Nguyen, Kristbjorn Gudmundsson
Keywords(s): Embryonic, Fetal, Hemoglobin, SETBP1, Sickle Cell Disease, XP01, β-thalassemia
Category(s): Therapeutic
Targeted Therapeutics for Treating Sickle Cell Disease and β-thalassemia - (HJF 596-21)
Novel therapeutics for sickle cell disease and β-thalassemia are available for licensing and collaboration. This technology was developed by scientists from the Uniformed Services University of Health Sciences and assigned to HJF. Applications and Advantages Novel therapeutic targets for sickle cell disease and β-thalassemia. Several...
Published: 10/17/2024   |   Updated: 6/28/2022   |   Inventor(s): Yang (Dennis) Du
Keywords(s): Sickle Cell Disease, Therapeutics, β-globinopathies, β-thalassemia
Category(s): Therapeutic